Gryphon Financial Partners’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $323K | Buy |
3,566
+589
| +20% | +$49.3K | 0.03% | 293 |
|
|
2026
Q1 | $238K | Sell |
2,977
-67
| -2% | -$5.52K | 0.02% | 324 |
|
|
2025
Q4 | $260K | Sell |
3,044
-38
| -1% | -$3.12K | 0.03% | 299 |
|
|
2025
Q3 | $240K | Buy |
3,082
+336
| +12% | +$26.3K | 0.03% | 291 |
|
|
2025
Q2 | $215K | Buy |
+2,746
| New | +$205K | 0.03% | 293 |
|
|
2025
Q1 | – | Sell |
-2,946
| Closed | -$218K | – | 281 |
|
|
2024
Q4 | $218K | Sell |
2,946
-1,374
| -32% | -$96.2K | 0.03% | 239 |
|
|
2024
Q3 | $285K | Sell |
4,320
-365
| -8% | -$26.5K | 0.04% | 241 |
|
|
2024
Q2 | $433K | Sell |
4,685
-457
| -9% | -$40.5K | 0.06% | 180 |
|
|
2024
Q1 | $491K | Sell |
5,142
-1,312
| -20% | -$110K | 0.08% | 157 |
|
|
2023
Q4 | $681K | Buy |
6,454
+1,698
| +36% | +$118K | 0.12% | 119 |
|
|
2023
Q3 | $329K | Buy |
4,756
+3,432
| +259% | +$276K | 0.08% | 135 |
|
|
2023
Q2 | $125K | Sell |
1,324
-3,616
| -73% | -$314K | 0.03% | 196 |
|
|
2023
Q1 | $409K | Buy |
4,940
+5
| +0.1% | +$393 | 0.09% | 121 |
|
|
2022
Q4 | $368K | Buy |
4,935
+157
| +3% | +$12.1K | 0.09% | 131 |
|
|
2022
Q3 | $395K | Sell |
4,778
-165
| -3% | -$15.9K | 0.1% | 115 |
|
|
2022
Q2 | $470K | Buy |
4,943
+365
| +8% | +$37.8K | 0.11% | 102 |
|
|
2022
Q1 | $538K | Sell |
4,578
-698
| -13% | -$78.3K | 0.11% | 106 |
|
|
2021
Q4 | $684K | Sell |
5,276
-409
| -7% | -$47.7K | 0.13% | 95 |
|
|
2021
Q3 | $643K | Sell |
5,685
-571
| -9% | -$65.2K | 0.14% | 86 |
|
|
2021
Q2 | $520K | Buy |
6,256
+126
| +2% | +$11.9K | 0.12% | 88 |
|
|
2021
Q1 | $512K | Sell |
6,130
-18
| -0.3% | -$1.52K | 0.12% | 94 |
|
|
2020
Q4 | $561K | Sell |
6,148
-11
| -0.2% | -$912 | 0.14% | 79 |
|
|
2020
Q3 | $492K | Sell |
6,159
-24
| -0.4% | -$1.87K | 0.15% | 78 |
|
|
2020
Q2 | $428K | Sell |
6,183
-1,623
| -21% | -$115K | 0.13% | 82 |
|
|
2020
Q1 | $491K | Sell |
7,806
-585
| -7% | -$42.2K | 0.18% | 61 |
|
|
2019
Q4 | $653K | Buy |
8,391
+48
| +0.6% | +$3.75K | 0.17% | 66 |
|
|
2019
Q3 | $611K | Sell |
8,343
-162
| -2% | -$11.4K | 0.18% | 64 |
|
|
2019
Q2 | $524K | Sell |
8,505
-108
| -1% | -$6.53K | 0.15% | 76 |
|
|
2019
Q1 | $550K | Hold |
8,613
| – | – | 0.16% | 70 |
|
|
2018
Q4 | $440K | Sell |
8,613
-162
| -2% | -$8.2K | 0.11% | 127 |
|
|
2018
Q3 | $509K | Buy |
8,775
+8,088
| +1,177% | +$396K | 0.15% | 78 |
|
|
2018
Q2 | $34K | Hold |
687
| – | – | 0.02% | 290 |
|
|
2018
Q1 | $32K | Sell |
687
-42
| -6% | -$1.82K | 0.02% | 299 |
|
|
2017
Q4 | $27K | Buy |
+729
| New | +$26.8K | 0.02% | 350 |
|
Other funds holding EW
Gryphon Financial Partners's EW Position: Q2 2026 in Review
Gryphon Financial Partners increased its Edwards Lifesciences (EW) stake by 20% in Q2 2026, buying an estimated $49.3K and bringing the position to 3,566 shares worth $323K. The position accounts for 0.03% of the portfolio, ranked #293.
Gryphon Financial Partners first reported a position in EW in Q4 2017 and has held it in 34 quarters since. The position peaked at $684K in Q4 2021. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Gryphon Financial Partners held 3,566 shares of Edwards Lifesciences worth $323K as of Q2 2026.
- Gryphon Financial Partners bought 589 Edwards Lifesciences shares in Q2 2026, an estimated $49.3K.
- Edwards Lifesciences made up 0.03% of Gryphon Financial Partners's portfolio in Q2 2026, its #293 holding.
- Gryphon Financial Partners first reported a position in Edwards Lifesciences in Q4 2017 and has held it in 34 quarters since.
- Gryphon Financial Partners's Edwards Lifesciences position peaked at $684K in Q4 2021.
- 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Gryphon Financial Partners's 13F filing for Q2 2026, filed 5 Aug 2026.